Effectiveness of Blood Clot Medication With Concomitant Blood Pressure Medication
Status:
Unknown status
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
Patients in intensive care units have higher risks for developing blood clots. Arixtra
inhibits blood clot formation by binding with the blood clotting factor, Xa. Critical
illnesses and, specifically, medications given in the ICU to increase arterial blood pressure
(vasopressors) may impair the absorption of drugs like Arixtra that are given subcutaneously.
The study will measure the levels of Arixtra in blood comparing those subjects who are and
those subjects who are not on blood pressure medication.